Top

Published in:

01-08-2013 | Research Article

Serum GFAP autoantibody as an ELISA-detectable glioma marker

Authors: Ping Wei, Wei Zhang, Liu-Song Yang, Hai-Shi Zhang, Xiao-En Xu, Ying-Hua Jiang, Feng-Ping Huang, Qian Shi

Published in: Tumor Biology | Issue 4/2013

Abstract

Glioma is the most common primary brain tumor, yet the high cost of diagnostic imaging has made early detection of asymptomatic glioma a formidable challenge. Thus, the development of a convenient, sensitive, and cost-effective diagnostic strategy, such as enzyme-linked immunosorbent assay (ELISA) based on glioma-specific and World Health Organization (WHO) grade-specific autoantibody serum markers, is necessary. To this end, a comparative proteomic analysis based on two-dimensional western blotting was carried out with the sera of glioma patients and normal controls. Of the 11 novel glioma-expressed autoantibodies, the autoantibody against glial fibrillary acidic protein (GFAP) showed the highest differential expression. To investigate the potential clinical utility of the GFAP autoantibody as an early diagnostic marker for glioma, an ELISA-based assay was developed and validated with sera from glioma patients with WHO grades II (n = 19), III (n = 17), and IV (n = 24). The GFAP autoantibody level directly correlated with WHO grade and tumor volume. Sera from patients of non-glioma brain tumors, as well as non-brain tumors, showed much lower levels of GFAP autoantibody than those of the glioma patients, indicating that elevated GFAP autoantibody is specific to glioma patients. Analysis of the receiver operating characteristics curve suggested that the new ELISA has good distinguishing power and sensitivity for diagnosing glioma patients. This is the first ELISA assay developed for an autoantibody of a glioma antigen and may prove valuable for the clinical detection of glioma.

Parkinm DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.CrossRef

Somasundaram K, Nijaguna MB, Kumar DM. Serum proteomics of glioma: methods and applications. Expert Rev Mol Diagn. 2009;9:695–707.PubMedCrossRef

Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer. 2007;110:13–24.PubMedCrossRef

Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys. 1998;40:51–5.PubMedCrossRef

Fredman P, von Holst H, Collins VP, Granholm L, Svennerholm L. Sialyllactotetraosylceramide, a ganglioside marker for human malignant gliomas. J Neurochem. 1988;50:912–9.PubMedCrossRef

Fukuda ME, Iwadate Y, Machida T, Hiwasa T, Nimura Y, Nagai Y, et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res. 2005;65:5190–4.PubMedCrossRef

Jung CS, Foerch C, Schanzer A, Heck A, Plate KH, Seifert V, et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain. 2007;130:3336–41.PubMedCrossRef

Petrik V, Saadoun S, Loosemore A, Hobbs J, Opstad KS, Sheldon J, et al. Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma. Clin Chem. 2008;54:713–22.PubMedCrossRef

Ammirati M, Rao S, Granger G. Detection of TNF inhibitors (soluble receptors) in the sera and tumor cyst fluid of patients with malignant astrocytomas of the brain. Front Biosci. 2001;6:B17–24.PubMedCrossRef

10.

Todaro L, Christiansen S, Varela M, Campodonico P, Pallotta MG, Lastiri J, et al. Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors. J Neurooncol. 2007;83:135–44.PubMedCrossRef

11.

Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res. 1999;5:985–90.PubMed

12.

Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res. 2006;12:5698–704.PubMedCrossRef

13.

Kijanka G, Murphy D. Protein arrays as tools for serum autoantibody marker discovery in cancer. J Proteomics. 2009;72:936–44.PubMedCrossRef

14.

Lleo A, Invernizzi P, Gao B, Podda M, Gershwin ME. Definition of human autoimmunity—autoantibodies versus autoimmune disease. Autoimmun Rev. 2010;9:A259–66.PubMedCrossRef

15.

Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009;276:6880–904.PubMedCrossRef

16.

Nesterova MV, Johnson N, Cheadle C, Bates SE, Mani S, Stratakis CA, et al. Autoantibody cancer biomarker: extracellular protein kinase A. Cancer Res. 2006;66:8971–4.PubMedCrossRef

17.

Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000;60:1777–88.PubMed

18.

Fernandez-Madrid F, Tang N, Alansari H, Granda JL, Tait L, Amirikia KC, et al. Autoantibodies to annexin XI-A and other autoantigens in the diagnosis of breast cancer. Cancer Res. 2004;64:5089–96.PubMedCrossRef

19.

Zhong L, Ge K, Zu JC, Zhao LH, Shen WK, Wang JF, et al. Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Res. 2008;10:R40.PubMedCrossRef

20.

Bradley SV, Oravecz-Wilson KI, Bougeard G, Mizukami I, Li L, Munaco AJ, et al. Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer. Cancer Res. 2005;65:4126–33.PubMedCrossRef

21.

Yang F, Xiao ZQ, Zhang XZ, Li C, Zhang PF, Li MY, et al. Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res. 2007;6:751–8.PubMedCrossRef

22.

Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol. 2008;26:5060–6.PubMedCrossRef

23.

Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Tureci O, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax. 2008;63:228–33.PubMedCrossRef

24.

Ran Y, Hu H, Zhou Z, Yu L, Sun L, Pan J, et al. Profiling tumor-associated autoantibodies for the detection of colon cancer. Clin Cancer Res. 2008;14:2696–700.PubMedCrossRef

25.

Rainov NG, Dobberstein KU, Fittkau M, Bahn H, Holzhausen HJ, Gantchev L, et al. Absence of p53 autoantibodies in sera from glioma patients. Clin Cancer Res. 1995;1:775–81.PubMed

26.

Pallasch CP, Struss AK, Munnia A, Konig J, Steudel WI, Fischer U, et al. Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer. 2005;117:456–9.PubMedCrossRef

27.

Soling A, Plugge EM, Schmitz M, Weigle B, Jacob R, Illert J, et al. Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors. Int J Oncol. 2007;30:123–8.PubMed

28.

Ludwig N, Keller A, Comtesse N, Rheinheimer S, Pallasch C, Fischer U, et al. Pattern of serum autoantibodies allows accurate distinction between a tumor and pathologies of the same organ. Clin Cancer Res. 2008;14:4767–74.PubMedCrossRef

29.

Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, Wood WC, et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol. 2011;22:383–9.PubMedCrossRef

30.

Murray A, Chapman CJ, Healey G, Peek LJ, Parsons G, Baldwin D, et al. Technical validation of an autoantibody test for lung cancer. Ann Oncol. 2010;21:1687–93.PubMedCrossRef

31.

Tran Thang NN, Derouazi M, Philippin G, Arcidiaco S, Di Berardino-Besson W, Masson F, et al. Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development. Cancer Res. 2010;70:4829–39.PubMedCrossRef

32.

Eng LF, Vanderhaeghen JJ, Bignami A, Gerstl B. An acidic protein isolated from fibrous astrocytes. Brain Res. 1971;28:351–4.PubMedCrossRef

33.

Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem Res. 2000;25:1439–51.PubMedCrossRef

34.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.PubMedCrossRef

35.

Donato V, Papaleo A, Castrichino A, Banelli E, Giangaspero F, Salvati M, et al. Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori. 2007;93:248–56.PubMed

36.

Wurschmidt F, Bunemann H, Heilmann HP. Prognostic factors in high-grade malignant glioma. A multivariate analysis of 76 cases with postoperative radiotherapy. Strahlenther Onkol. 1995;171:315–21.PubMed

37.

Shaw EG, Scheithauer BW, O'Fallon JR, Davis DH. Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery. 1994;34:577–82.PubMedCrossRef

Title: Serum GFAP autoantibody as an ELISA-detectable glioma marker
Authors: Ping Wei
Wei Zhang
Liu-Song Yang
Hai-Shi Zhang
Xiao-En Xu
Ying-Hua Jiang
Feng-Ping Huang
Qian Shi
Publication date: 01-08-2013
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-0770-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

The role of low-molecular-weight protein tyrosine phosphatase (LMW-PTP ACP1) in oncogenesis

Associations of CYP2E1 rs2031920 and rs3813867 polymorphisms with colorectal cancer risk: a systemic review and meta-analysis

RETRACTED ARTICLE: XRCC3 T241M polymorphism is associated risk of hepatocellular carcinoma in the Chinese

CIP2A expression is associated with altered expression of epithelial–mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma

Clinicopathological significance of BTF3 expression in colorectal cancer

Adenovirus arming human IL-24 inhibits neuroblastoma cell proliferation in vitro and xenograft tumor growth in vivo

Keynote webinar | Spotlight on antibody–drug conjugates in cancer